Gynecologic Oncology Group — CureCurrent

Published trials10

Recruiting shown0

Roles2

SourceClinicalTrials.gov

Clinical trials

10 shown

Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199NCT01445275 · lead sponsor · 2011-01-01

Incidence of Cancer in Women at Increased Genetic Risk of Ovarian CancerNCT01139957 · lead sponsor · 2010-06-07

Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial CancerNCT00807768 · lead sponsor · 2009-03-23

Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation CarriersNCT00899145 · lead sponsor · 2008-05-01

Studying Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation CarriersNCT00897455 · lead sponsor · 2008-04-01

Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both OvariesNCT00305695 · lead sponsor · 2005-11-28

Collecting Tumor Samples From Patients With Gynecological TumorsNCT00897442 · lead sponsor · 1992-06-01

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)NCT04634877 · collaborator · 2021-01-10

ACTIVE_NOT_RECRUITING

Clinical Effectiveness of First Trimester Pre-eclampsia Screening Program.NCT04021680 · collaborator · 2019-06-10

Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)NCT03740165 · collaborator · 2018-12-18

Sponsor roles

lead sponsor7

collaborator3

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.